Purpose. The unlabeled uses of intravenous immune globulin (IVIG) were reviewed. Summary. A literature review was conducted to identify studies examining the unlabeled uses of IVIG. A review of 138 clinical trial abstracts identified 10 trials examining 2 labeled uses (635 patients) and 128 trials examining 61 different off-label uses (6781 patients). The most common off-label indications included multiple sclerosis, graft-versus-host disease in transplant patients, prevention of antiphospholipid syndrome in miscarriage, Guillain-Barré syndrome, and progression of human immunodeficiency virus after delivery. The studies appeared to support many of the acceptable off-label uses cited by various guideline groups. A total of 276 case reports were identified, with 268 reports representing 156 different off-label uses (362 patients). Seven meta-analyses were identified, evaluating recurrent miscarriage, in vitro fertilization failure, infection in preterm infants, multiple sclerosis, immune thrombocytopenic purpura, and pemphigoid. With the exception of recurrent miscarriage and infection in preterm infants, the off-label use of IVIG for these indications was associated with positive outcomes. An examination of IVIG guidelines by specialty society, payer, and other review organizations revealed that the biomedical evidence supporting off-label uses is being interpreted in different ways. Health care institutions are strongly urged to approve and closely monitor specific uses of IVIG to reserve dwindling supplies for the "best-evidence" uses. Clinicians should be aware of the limits of knowledge in many off-label uses and exercise restraint in prescribing for unproven indications. Conclusion. A literature review identified more than 150 unlabeled uses of IVIG. The evidence for these uses is being interpreted in different ways by various reviewing organizations.
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ntravenous immune globulin (IVIG) has been used for the treatment of immunodeficiency disorders for more than 50 years. Advances in the purification and fractionation processes have allowed for an increasingly higher concentration of immunoglobulin G (IgG) in these products, the major immunoglobulin found in human blood. 1 The pharmacokinetics and varying product compositions of IVIG have been extensively detailed elsewhere. 2, 3 As of October 2007, a total of seven IVIG products are marketed in the United States: Carimune NF (CSL Behring, King of Prussia, PA), Flebogamma (Grifols, Los Angeles, CA), Gammagard Liquid (Baxter, Deerfield, IL), Gammagard S/D (Baxter), Gamunex (Bayer, Leverkusen, Germany), Octagam (Octapharma, Lachen, Switzerland), and Privigen (CSL Behring). 4 IVIG mechanisms of action are complex and include antiinfective, immunoregulatory, and antiinflammatory properties. In primary and secondary immunodeficiency diseases, IVIG restores normal humoral immune function by increasing antibody levels and possibly enhancing other immune functions, such as removing immunosuppressive complexes. 5, 6 Several mechanisms have been proposed for the immunomodulatory action of IVIG in autoimmune disorders. Short-term actions include neutralization of circulating autoantibodies or superantigens, blockade of Fc receptor-mediated events, and modulation of cytokines. Long-term IVIG therapy may promote down regulation of antibody production and regulate the production of helper or suppressor T-cell cytokines. 7 The antiinflammatory actions of IVIG may occur through several possible mechanisms, including the reduction of complementmediated damage, neutralization of microbial toxins, and activation of leukocytes. 6 Labeling approved by the Food and Drug Administration (FDA) for a prescription product like IVIG allows for the manufacturer to market the product for specific indications. In practice, however, clinicians can use IVIG for any indication for which they perceive a patient benefit. FDA does not restrict or interfere with the clinical practice of approved products and made the following statement in a 1998 guidance document to institutional review boards and clinical investigators 8 
:
Good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgment. If physicians use a product for an indication not in the approved labeling, they have the responsibility to be well informed about the product, to base its use on firm scientific rationale and on sound medical evidence, and to maintain records of the product's use and effects. Use of a marketed product in this manner when the intent is the 'practice of medicine' does not require the submission of an Investigational New Drug application (IND), Investigational Device Exemption (IDE) or review by an Institutional Review Board (IRB).
Economic issues and product availability have converged to make the continuing use of IVIG therapy challenging for health providers. Reductions in reimbursement by Medicare (causing shifts in the site of care from physician offices to hospitals), consolidation in manufacturers (leading to decreased production), and overall increases in the number of patients prescribed IVIG (many prescribed for unlabeled indications) have led to dramatic increases in pharmacy budgets with concomitant difficulties in acquiring the needed amount of product to treat all potential patients.
9,10

Status of IVIG
The marketing of IVIG products is approved by FDA for indications that may be categorized into replacement therapy, the treatment of autoimmune diseases, or passive immunotherapy. Labeled indications for IVIG preparations currently marketed in the United States are listed in Table 1 and include idiopathic thrombocytopenic purpura, primary immunodeficiency, chronic lymphocytic leukemia, and Kawasaki disease.
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The various uses of IVIG for unlabeled indications, however, far exceed uses for the labeled indications. These indications include the treatment of a host of immunologic, presumed immunologic, and idiopathic diseases involving nearly all organ systems. Over 150 unlabeled uses have been identified, including the most studied indications (e.g., multiple sclerosis, prevention of antiphospholipid syndrome in miscarriage, GuillainBarré syndrome) (eTable 1, available at www.ajhp.org). The majority of unlabeled indications of IVIG are derived mainly from anecdotal reports or inadequately controlled studies. 12 The likelihood of manufacturers pursuing the required clinical trials to gain new labeling is remote due to the high costs of conducting such trials, with no probable extra profits or competitive marketing advantages.
A University HealthSystem Consortium (UHC) electronic survey of pharmacy directors (n = 37) in January 2007 revealed that, on average, the majority of IVIG use (61%) was for outpatients. 13 Outpatient use of IVIG has increased in the past two years in 75% of respondents' institutions, remained the same in 19%, and decreased in 6%. Reasons given for the changes in outpatient use were related to an increase in patient volume (82%), changes in delivery site (hospitals treating patients previously seen in physician offices) (46%), previous inpatient treatment moving to outpatient clinics (25%), declining reimbursement by payers 
Labeled Indications for Intravenous Immune Globulin Preparations
Product
Primary Immunodeficiency
Idiopathic
Thrombocytopenic Purpura
Carimune NF (CSL Behring)
Chronic Lymphocytic Leukemia
Kawasaki Disease (18%), "dumping" of patients to hospitals (18%), new indications (14%), "cherry picking" of patients (11%), and a declining margin for specialty pharmacies (4%).
Administration
The dose and interval of IVIG administration are variable because of interpatient differences in the rate of IVIG catabolism.
14 Serum IgG concentrations can be used as a surrogate endpoint (with a goal of >500 to 600 mg/dL); however, treatment efficacy is best determined by the rate of recurrent infections and complications. IVIG dosages for the treatment of primary immunodeficiency disorders range from 0.2 to 0.8 g per kilogram of body weight, given every four weeks. Although IVIG products are generally well tolerated, specific properties may need to be considered for certain patient populations and may contribute to an increase in adverse events. Patients should be evaluated for potential risk factors, including renal dysfunction, cardiac impairment, diabetes mellitus, and the presence of antiimmunoglobulin A antibodies before therapy is initiated. Properties such as immunoglobulin A concentration, sugar and sodium content, osmolality, and pH may affect product selection. 6 
Recommendations
In September 1994, UHC convened a multidisciplinary expert panel to consider the appropriate use of IVIG. This group of 10 clinical experts reviewed graded published biomedical trial evidence prepared by UHC staff. Using an evidencebased, consensus-driven process, the expert panel determined that of the 54 unlabeled indications identified, 3 were considered acceptable for clinical use, 38 were not recommended, and 13 were not recommended for routine use but might be considered under limited circumstances. These recommendations were released to UHC member institutions in April 1995 and subsequently published in a peer-reviewed journal. 15 In the fall of 1998, UHC updated its review of the biomedical literature, reconvened the expert panel, and released new recommendations for IVIG use. 12 The expert panel determined that of 71 off-label indications reported, 3 were recommended, 51 were not recommended due to a lack of published efficacy evidence, and 17 were not recommended for routine use but might be considered under limited circumstances.
Since the March 1999 release of the UHC IVIG use guidelines to UHC members, two additional consensus statements have been published. The first was published in 2003 by the Autoimmune Mucocutaneous Blistering Diseases Consensus Development Group 16 ; the second statement, issued by the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma, and Immunology, followed in 2006. 17 The first consensus statement, developed by an international group of 35 clinicians (mostly dermatologists) was funded by a grant from Bayer Corporation and focused on five mucocutaneous diseases. The use of IVIG was supported in the treatment of pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and epidermolysis bullosa acquisita, but the authors emphasized the need for larger multicenter trials. The American Academy of Allergy, Asthma, and Immunology sponsored an IVIG expert panel that reviewed graded evidence from the biomedical literature through November 2005 in five major categories of unlabeled uses. This group comprised 16 clinical experts from a variety of medical specialties and was funded by a grant from Octapharma USA Inc. In reviewing primary and secondary immune deficiencies, the committee concluded that 2 uses were definitely beneficial, 3 were probably beneficial, 1 might provide benefit, and 2 were unlikely to be beneficial. For various autoimmune diseases, the committee concluded that 2 uses were definitely beneficial, 2 were probably beneficial, 10 might provide benefit, and 2 were unlikely to be beneficial. For neuroimmunologic disorders, 3 uses were found to be definitely beneficial, 4 were probably beneficial, 12 might provide benefit, and 5 were unlikely to be beneficial. For infection-related diseases, 2 uses were deemed definitely beneficial, 5 were probably beneficial, 4 might provide benefit, and 3 were unlikely to be beneficial. For a final miscellaneous category of uses, the committee classified 1 use as probably beneficial and 7 as unlikely to be beneficial; the committee concluded that 10 uses might provide benefit. In summary, of the 80 unlabeled uses considered by the members of the primary immunodeficiency committee, 9 were definitely beneficial, 15 were probably beneficial, 37 might provide benefit, and 19 were unlikely to be beneficial. Only 19 (24%) of reviewed unlabeled uses were considered unlikely to be beneficial.
Other organizations have also published coverage guidelines for IVIG. Medical policies from payer organizations vary considerably. While Aetna's 2006 medical policy cited 28 unlabeled uses of IVIG as medically necessary and 87 as experimental or investigational, 18 Blue Cross of California's policy allows for 17 unlabeled indications for IVIG without addressing other unapproved uses. 19 The Medical Letter on Drugs and Therapeutics published a summary review of IVIG uses in December 2006, advising that 14 of the 19 unlabeled indications reviewed are reasonable therapeutic options. 20 A comparative review of the guidelines provided by these six organizations (appendix) revealed the existence of 153 unlabeled uses of IVIG, 43 (28%) of which were reviewed by at least three organizations. Indications were ranked by these organiza-tions as not recommended (scored as 0), potentially beneficial (1), and acceptable (2). Only 34 indications (22%) were scored an average of 1.5 or higher by the various groups, suggesting that at least one organization found the use to be beneficial. Only 11 indications (7%) averaged 1.5 or higher by ratings from at least three organizations.
Drug-use evaluations
Three drug-use evaluation studies were conducted to compare various uses of IVIG with established guidelines or protocols. Studies conducted in the United States included one single-center study by Darabi et al. 21 and a multicenter study conducted by Chen et al. 22 Another multicenter study evaluated the use of IVIG in four hospitals in Canada. 23 After reviewing IVIG use in 251 patients from 12 U.S. academic health centers, Chen et al. concluded, using 1995 UHC guidelines, that 107 patients (43%) received IVIG for labeled indications, 130 (52%) for unlabeled indications, and 14 (5%) for undefined treatment. Examination of the unlabeled subset revealed that the indications of 95 patients (73%) met guidelines and 35 (27%) did not.
Darabi et al. 21 retrospectively reviewed IVIG use for calendar year 2004 at Massachusetts General Hospital and found that it was given to 194 patients for the following indications: chronic neuropathy (n = 56), secondary hypogammaglobulinemia (n = 34), idiopathic thrombocytopenia (n = 20), primary hypogammaglobulinemia (n = 18), renal transplantation (n = 12), myasthenia gravis (n = 9), Guillain-Barré syndrome (n = 8), common variable immunodeficiency (n = 8), necrotizing fascitis (n = 6), autoimmune hemolytic anemia (n = 6), Kawasaki disease (n = 5), and various other uses (n = 12). A total of 104 patients (54%) received IVIG for unlabeled indications, consistent with the findings of Chen et al. 22 Darabi and colleagues 21 stated that the "majority" of unlabeled IVIG use was consistent with the hospital's guidelines, though these guidelines were not defined in the article.
Finally, Pendergrast et al. 23 reported the results of IVIG use at four Toronto hospitals from 1995 through 2000. In 429 patients, IVIG use was distributed among the following types of conditions: neurologic (26%), hematologic (24%), bone marrow transplants (15%), infectious disease (13%), dermatological (6%), rheumatology (3%), and other or unknown (13%). The authors stated that most (75%) of the IVIG use in this retrospective study would be considered reasonable, though no specific guidelines were offered. A review of the study's published data revealed that 156 of 375 patients received IVIG for indications consistent with those on FDA-approved labeling, similar to the findings of the two above-mentioned IVIG-use studies.
Unlabeled uses
Clinical studies in the biomedical literature on unlabeled uses of IVIG preparations were identified by searching the PUBMED (MEDLINE+) database using the key terms immune globulin and intravenous (administration and dosage) or immune globulin and intravenous (therapeutic use). The search was limited to articles in English, clinical trials, meta-analyses, randomized controlled trials, and case reports published between January 1, 1998, and January 1, 2006. This time period was chosen to examine the extent of new clinical publications regarding IVIG since the last UHC IVIG technology assessment was published in 1999. 12 Several review articles on the use of IVIG were also identified. [24] [25] [26] [27] A total of 138 IVIG clinical trial citations were identified, with 10 trials dedicated to examining two labeled uses (total of 635 patients) and 128 trials (eTable 1, available at www.ajhp.org) examining 61 different unlabeled uses (total of 6781 patients). While a properly designed and powered randomized clinical trial is considered the strongest form of clinical evidence, only a limited amount of information can be discerned from reviewing abstracts, as was done for this review. A list of retrieved citations is provided in eAppendix A (available at www.ajhp.org). The retrieved clinical studies appeared to support many of the acceptable unlabeled uses cited by various guideline groups. The top unlabeled indications reported in clinical trials, ranked by number of patients, included multiple sclerosis, graft-versus-host disease in transplant recipients, prevention of antiphospholipid syndrome in miscarriage, Guillain-Barré syndrome, and human immunodeficiency syndrome progression after delivery (eTable 1). An average score for each indication was calculated by dividing the sum of recommendation scores by the number of rating organizations (appendix). A total of 17 (28%) of 61 unlabeled uses scored an average rating of ≥1.0 (i.e., conditional acceptance). However, more than 50% of the supportive clinical trials included study populations of fewer than 36 patients.
A total of 276 case reports were identified, with 8 reports concerning labeled use (12 total patients) and 268 reports (eTable 2, available at www.ajhp.org) representing 156 different unlabeled uses (362 total patients). Patient outcomes as discerned from published abstracts were rated as positive for 267 patients (74%), partial for 8 patients, and nonresponsive for 27 patients. Absence of an outcome in eTable 2 indicates a lack of discernible outcomes from reviewing the respective abstract or lack of an abstract altogether. Of the 156 different unlabeled uses mentioned in case reports, 94 (60%) were not covered by any organizational guidelines reviewed for this article. Unlabeled uses examined Am J Health-Syst Pharm-Vol 65 Oct 1, 2008 in case studies consisting of more than 10 patients included peripheral neuropathy, toxic epidermal necrolysis, myasthenia gravis, and StevensJohnson syndrome (eTable 2).
Meta-analyses were also reviewed, including seven published reports (Table 2) . [28] [29] [30] [31] [32] [33] [34] The reports reviewed randomized controlled trials evaluating the use of IVIG for indications including recurrent miscarriage, in vitro fertilization failure, infection in preterm infants, multiple sclerosis, immune thrombocytopenic purpura, and pemphigoid. With the exception of recurrent miscarriage and infection in preterm infants, the unlabeled use of IVIG for these indications resulted in positive outcomes.
Economic and reimbursement issues
Coverage and payment for IVIG therapy vary by payer organizations. Few payers differentiate between labeled and unlabeled uses in the outpatient environment where most therapy is delivered. 18, 19 Drug cost payment is reported to be decreasing, while product acquisition costs are increasing. 35, 36 On an inpatient basis, diagnosis-related group-based hospital reimbursement for Medicare and Medicaid recipients typically does not provide additional payments for use of expensive drug therapy. A standard course of IVIG for an adult costs approximately $2,700 per infusion. The need for multiple courses of treatment (e.g., monthly) for many immunodeficiency disorders, often at higher-than-labeled doses, can quickly increase annual IVIG costs per patient to $50,000 or more.
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Discussion
The biomedical literature detailing IVIG use continues to expand, with 138 new clinical trials, 276 case reports, and 7 meta-analyses between January 1998 and December 2006 investigating 156 unlabeled uses. This trend is likely to continue, as many clinical disciplines are involved in potential uses of IVIG (e.g., neurology, hematology, dermatology, infectious diseases, rheumatology). An examination of recent IVIG guidelines by specialty society, payer, and other review organizations revealed that the biomedical evidence is being interpreted in different ways regarding the acceptability of many unlabeled uses. A large degree of inconsistency exists concerning how unlabeled uses are evaluated and scored. Health care institutions are strongly urged to convene a local clinical committee (e.g., pharmacy and therapeutics) to review and approve specific uses of IVIG. These approved uses should be closely monitored to reserve dwindling supplies of IVIG products for the "best-evidence" uses. Coverage and reimbursement policies from hospitals' major payers need to be evaluated to ensure adequate cost recovery. Clinicians should be aware of the limits of knowledge in many unlabeled uses and exercise restraint in prescribing for unproven indications. Institutional control mechanisms may need to be implemented, such as specialty consultations and restricted prescribing authority.
Conclusion
A literature review identified more than 150 unlabeled uses of IVIG. The evidence for these uses is being interpreted in different ways by various reviewing organizations. 
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